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Objective. This study aimed to deﬁne CBCT as a technique for postimplantation in vivo examination of porous hydroxyapatite
and aluminium-oxide orbital implant shape, volume and density changes. Methods and Materials. CBCT was used to evaluate
30 enucleated patients treated with spherical polyglactin 910 wrapped hydroxyapatite and aluminum-oxide orbital implants. The
mean duration of patient followup was 3.2 years or 1338 days with a range of 0.2 to 7.2 years or 79 to 2636 days in a population
with an average age of 40.8 years. Results. The resolution of currently clinically used CBCT equipment allowed detailed structural
observation of the orbital hydroxyapatite implants with some modiﬁcations. Volume and shape estimations were possible while
density evaluation was more complicated compared to medical source computed tomography. The mean densities of the orbital
implants were followed and a consistent gradual decrease identiﬁed from the beginning of implantation which was better deﬁned
after the applied correction procedure. Conclusion. CBCT with lower dosages of radiation exposure can be used to follow changes
in implanted high-density porous structures. The density evaluation is possible with calibration modiﬁcations. Changes in orbital
implant densities identiﬁed in this study may correspond to healing and maturation of soft tissues surrounding and penetrating
the implants.
1.Introduction
Enucleation has long been used for the treatment of ocular
diseases such as intraocular malignancy, severe trauma, and
blind painful eye. The major purpose of enucleation is to
remove the diseased globe intact and to provide a cosmet-
ically acceptable appearance [1]. The ﬁrst orbital removal
for medical treatment was performed in 1583. In 1885 the
ﬁrst orbital implants to replace the obvious cosmetically
deleterious volume loss after evisceration were hollow glass,
g o l d ,o rs i l v e rs p h e r e s[ 1–3]. Since then numerous studies
describing diﬀerent types of enucleation techniques and
various types of orbital implants have been published [4–
10]. These implanted spheres are permanently buried within
the soft tissues of the orbit. Later a cosmetically pleasing,
removable shield-like ocular prosthesis made from glass
or medical grade acrylic is placed between the remaining
conjunctiva and eyelids and supported by the sphere-shaped
orbital implant.
The characteristics of an ideal orbital implant include
adequatevolumereplacementofthelostglobe,goodmotility
and support transmitted to the overlying ocular prosthesis,
low rate of complications, and with an economical cost.
The orbital implant should be technically simple to implant,
biocompatible, and nondegradable as the orbital implant is
regarded as being permanent.
Porous orbital implants are preferred with porosity rates
of 80% [11] and pore diameters of 150µm to 400µmw h i c h
favour tissue ingrowth [12]. The most commonly used
porous materials for spherical orbital implants include2 International Journal of Biomaterials
xenografts such as coralline, bovine bone scaﬀolds, or syn-
thetic materials such as hydroxyapatite (HA), aluminium
oxide (AO), and porous polyethylene [13–30]. HA has been
used as a bone substitute in orthopaedics and oral and
maxillofacial surgery since 1975. HA received FDA approval
for use as an orbital implant in 1989 (Bio-Eye, Integrated
Orbital Implants, San Diego, CA) [31].
There is little information about composition, density,
volume, and shape changes of AO and HA implants in the
enucleated orbit. When follow-up imaging is required then
medical source computed tomography (MSCT) has been
used [12–14]. MSCT has the disadvantage of a signiﬁcant
radiation dose with each examination.
Other imaging options include bone scans and mag-
netic resonance imaging (MRI). Bone scans require the
intravenous injection of radionucleotide material while MRI
scans are enhanced by the intravenous injection of gadolin-
ium dye. Both modalities have great future potential.
Intraorbital HA implant examination with cone beam
computed tomography (CBCT) with lower radiation expo-
sure than MSCT may be a simpler and reliable clinical alter-
native to orbital implant monitoring and followup which has
yet to be evaluated.
CBCT was described in 1982 [19] and recently applied
todentomaxillofacialdiagnostics.Thisradiologicmodalityis
analternativeinsteadofMSCTwhichisreliableforthedetec-
tion of soft and hard tissues which are numerically described
by Hounsﬁeld units (HU).
In the past CBCT was less accurate than MSCT in HU
density measurements so that only the quantitative estima-
tion of the tissues was possible [20–26]. However recent
CBCTs use higher isometric voxel resolution from 72 to
400µm. MSCT voxels are usually not isometric and larger
than 250µm. Generally image noise is higher with CBCT
[27],whilethedoseofradiationismuchlower[21].Theﬁeld
of view (FOV) of dental and maxillofacial CBCTs includes
only a part of the head and neck region resulting in more
artifact [28] while the FOV with MSCT can incorporate as
much of the body as necessary. However, monitoring speciﬁc
anatomic areas can be performed with CBCT using less
radiation.
CBCT can be used for the preoperative evaluation of cal-
ciﬁed bone-like structures. Attempts to compensate for the
HU density distortion or inaccuracy have been resolved with
conversion coeﬃcients [29, 30]. CBCTs are less expensive
than MSCT making CBCT suitable for even single dental
oﬃcesormedicalclinics[19,21].MoreoverCBCTcombined
with other radiological modalities is another option.
CBCT may be potentially useful in tissue engineering
paradigms which may require long-term monitoring of
scaﬀolds in a noninvasive manner with the lowest possible
doses of radiation. The enucleated orbit provides a unique
modeltoevaluateporousscaﬀoldmaterialafterimplantation
in the orbit, a cavity with varying tissue densities.
This study evaluates the possible role of CBCT in the
post operative monitoring of the orbit, a speciﬁc and well-
deﬁned anatomic structure, with a porous AO and HA
implant. Speciﬁcally the aim of this study was to examine
Figure 1: Microstructure of the HA orbital implant. A planar
reconstruction of a native 18mm-diameter HA orbital implant.
Acquisition performed with microCT applying 7.815 micrometer
voxel size (SkyScan, Kontich, Belgium).
Figure 2: HA orbital implant with the polyglactin 910 mesh cover-
ing at the time of implantation.
orbital implants for shape, volumetric, and density changes
following implantation.
2.MaterialsandMethod
2.1. Surgical Procedure. The authors received the ethical
approval of the Semmelweis University to conduct this study
and complied with institutional ethical use protocols and
the guidelines of the Helsinki Declaration. A total of 30
patients requiring enucleation of the globe were treated with
spherical HA and AO orbital implants (France Chirurgie
Instrumentation FCI, Issy-Les-Moulineaux, France). The
reason for enucleation was intraocular tumor in 10 cases,
severe trauma in 10 cases, blind painful eye in 8 cases,
microphthalmos in 1 case, and microphthalmos with cyst in
1 case. The diameters of the spherical implants were: 16mm
in one case, 18mm in 13 cases, and 20mm in 16 cases
(Figures 1 and 2).
Implantation of spherical HA and AO included the fol-
lowing steps. A conjunctival peritomy was performed secur-
ing the muscle belly of each of the four rectus muscles with
a double-armed suture just behind its insertion on the globe.
Then disinsertion of the four rectus muscles was performedInternational Journal of Biomaterials 3
sequentially. Then globe was then removed. A set of sizing
spheres allowed determination of the size of the orbital
implant to be used. Then a spherical HA orbital spherical
implant wrapped in polyglactin 910 mesh (Vicryl Mesh
Ethicon Inc., Sommerville NJ, USA) or AO was inserted into
the muscle cone. The orbital implant was the proper size
when it was the largest implant that could be placed into
the depth of the orbit. The horizontal and vertical rectus
muscles were brought together over the implanted sphere
withattachmentofthemusclestotheVicrylmesh.Thetenon
fascia was closed over the muscles and sphere horizontally.
Finally the conjunctiva was closed.
In the postoperative phase a ﬁrm pressure dressing was
used for 4–6 days. Topical antibiotics are applied 4-5 times
daily for 4 weeks. The socket was ﬁt with an artiﬁcial eye
6–8 weeks postoperatively provided that all oedema had
subsided.
2.2. Radiographic Methods. Since the numerous methods
for porous structure estimations are unsuitable for in vivo
utilization, the least invasive method using CBCT was used
in this study. A large volume CBCT scanner, an iCat Classic
(Xoran Technologies, Ann Arbour Michigan, USA) with
the following characteristics 120KV, pixel size: 0.25mm,
slice increment 0.25mm, FOV 16cm was used for porous
structure evaluation of the 30 patients.
Hounsﬁeld units consist of a linear transformation of
the original linear attenuation coeﬃcient measurement into
one in which the radiodensity of distilled water at standard
pressureandtemperature(STP)isdeﬁnedaszeroHounsﬁeld
units (HU), while the radiodensity of air at STP is deﬁned as
−1000HU.
Deﬁnition of Hounsﬁeld units is
HU =
µX −µwater
µwater −µair
×1000. (1)
This deﬁnition is essential for MSCT scanners which are
calibrated with reference to water.
The CBCT also uses a linear Hounsﬁeld unit scale which
is not calibrated with water on a regular basis. Calibrations
c a nb ed o n ew i t ht w od i ﬀerent linear attenuation materials
by measuring the HU in the CBCT and MSCT systems
(Figure 3).
The greater the diﬀerence in the attenuation of the two
materials,withinthelinearfunctionrange,themoreaccurate
the calibration is. The HU acquired by the CBCT can be
transformed to the conventional MSCT-like HU scale.
There can be a diﬀerence between the linear attenuation
coeﬃcient and HU with each CBCT scanning procedure.
ThereforeeachCBCTacquisitionrequiredaseparatecalibra-
tion in this study.
A dedicated volume bordered by the inferior, superior,
lateral orbital margins and the posterior part of the sella
turcica were separated from the rest of the captured images
and termed the dedicated volume (DV) (Figures 4, 5, 6,a n d
7).
This volume contained decreased CBCT-related artefacts
and was the focus of this experiment. The gross volume of
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Figure 3: The conventional calibrated (MSCT) and noncalibrated
(CBCT) function of the attenuation coeﬃcient and HU. The
conventional calibration is represented by an interrupted blue line.
The MSCT is calibrated with this method. These functions are
diﬀerent with CBCT scanners as this calibration is lacking. Two
examples are shown as noninterrupted black lines.
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Figure 4: Multiplanar reconstruction (MPR) of the dedicated
orbital volume (DV). Axial view.
the orbital implants was known to be 16, 18, or 20mm-
diameter spheres and the corresponding diameter spherical
object used to determine the orbital implant volume (OI).
For calibration purposes and to correct for orbital
implant HU values two objects with diﬀerent linear attenua-
tion coeﬃcient were chosen from the FOV. The ﬁrst object
was the corpus vitreum of the contralateral orbit, and its
isolated volume was referred as the contralateral corpus
vitreum volume (CV) (Figure 8).
This was assumed to be a constant density region, close
to the density of the water for all patients. The second object
for calibration was the maximum HU and maximum linear
attenuation coeﬃcient of the dedicated volume of the orbital
region.
The mean HU value, apparent density, the OI, and CV, as
well as the maximal HU value in the DV were recorded. An
independent investigator estimated orbital implant radius
diameterwiththeuseofaradiusbased-3-pointﬁttingsphere4 International Journal of Biomaterials
Figure 5: Multiplanar reconstruction (MPR) of the dedicated
orbital volume (DV). Coronal view.
Figure 6: Multi-planar reconstruction (MPR) of the dedicated
orbital volume (DV). Sagittal view.
Figure 7: Volume rendering of the dedicated orbital volume (DV).
The DV is illustrated (green) and the orbital implant (yellow).
Figure 8: Volume rendering of the scanned volume with the orbital
implant and the contralateral corpus vitreum (patient ID 1.27).
drawing method available with Mimics 12 software (Materi-
alise, Leuven, Belgium). The time between the implantation
and the date of scanning was also noted.
A control group was established using ten randomly
selected head and neck scans from an archived past data pool
of MSCT scans from a General Electric, LightSpeed Ultra
MSCT scanner (Baltimore MD, USA) with the following
characteristics:120KV,246.35mAs,pixelsize0.326mm,slice
increment 0.625mm, FOV 16.7cm. The same standard and
boneplusacquisitionalgorithmwereusedinall10cases.The
mean HU value of the CV and the maximal HU value of the
DV were checked in the control group within the dedicated
orbitalregion.Theradiologicevaluationwasperformedwith
Mimics 12, while Excel (Microsoft, Redmond, WA, USA)
and SPSS (IBM, Somers NY, USA) programs were used for
statistical analysis.
3. Results
The results of the 10 head and neck control MSCT scans
showed that the mean CV density was 5.93HU (±3.97HU)
while the DV maximal HU value was 2024.67HU
(±103.49HU).
The results of the 30 patients’ iCAT CBCT scans are
shown in Table 1 in which the orange colour represents AlO
implants and light blue the HA implants. The ID numbers
with light colour indicate the excluded cases. The cases
appear in the consecutive order in which they were scanned.
After review of the quality of the CBCT scans by an
independent observer, two patients were excluded from the
study. One was excluded because of noncoherent scanning
FOV due to inadequate head positioning which resulted in
poor image quality. The second patient was a trauma patient
who was excluded because there was high-density metal
nearby causing artefacts beyond the average noise levels.
4. Discussion
Orbital implants can be classiﬁed as porous and nonporous.
The porous orbital implants are composed of either HA,
porous polyethylene (Medpor), or aluminium [1]. HA
orbital implants were introduced by Perry in 1985 [31],
and porous polyethylene orbital implants were introduced in
1989.Porousstructuresallowﬁbrovascularingrowthintothe
implant and integration with orbital tissues [1].Mostporous
implants used today are spherical.
Porous HA can be made by using the xenogenic matrix
from a speciﬁc genus of reef-building coral [1]a n dc h a n g e d
from calcium carbonate to calcium phosphate by a hydro-
thermal exchange reaction. HA can also be completely syn-
thetic. HA constitutes the primary inorganic portion of hu-
man bone. The porous form has a microarchitecture similar
to human cancellous bone with numerous interconnecting
channels with an average diameter of 500µm[ 1]. When HA
is implanted next to bone, new bone growth occurs within
its pores [1]. When HA is implanted within soft tissues,
ﬁbrovascular tissue grows into the pores [11, 12, 32].
Polyglactin 910 (Vicryl) wrapped HA implants wereused
in 18 and AlO in 12 patients in this double-blinded study.International Journal of Biomaterials 5
Table 1
Orbital implant Corpus vitreum Isolated volume
ID number
Diameter [mm] Lifespan
(days)
Volume mean
(HU)
Volume mean
SD (HU)
Corrected
mean (HU)
Volume mean
(HU)
Volume maximum
(HU) Measured Estimated
1.1 18 17,96 1051 −79 226 345 −425 1606
1.2 20 20,5 1420 623 281 754 −209 2006
1.3 20 19,96 1037 496 222 496 −344 3071
1.4 18 17,66 1361 566 337 713 −179 1920
1.5 20 20,5 1040 −42 101 434 −458 1476
1.6 18 16,26 2493 391 383 598 −147 1664
1.7 20 19,68 1911 579 304 825 −331 1884
1.8 20 19,58 1031 38 143 480 −446 1588
1.9 20 20,14 776 371 121 411 −87 2162
1.10 20 20,1 718 200 85 397 −198 1828
1.11 18 17,92 1196 350 105 360 −39 2146
1.12 20 20,1 1466 852 281 939 −104 1939
1.13 18 17,86 1831 773 383 784 −187 2273
1.14 18 17,4 317 308 128 417 −131 1995
1.15 18 17,88 1425 750 303 891 −127 1848
1.16 20 20,08 79 823 376 779 −131 2329
1.17 18 18,56 2151 728 361 790 −166 2106
1.18 18 17,92 2427 775 37 696 −78 2384
1.19 20 19,78 1237 302 102 424 −148 1995
1.20 20 20,26 1202 132 143 321 −212 1958
1.21 20 19,62 213 1432 521 786 326 3150
1.22 18 17,62 2219 414 253 695 −285 1736
1.23 20 19,72 1140 131 11 363 −228 1773
1.24 18 17,96 1903 729 388 810 −166 2051
1.25 16 17,78 2636 729 407 711 −77 2200
1.26 10 19,66 801 390 112 387 −29 2162
1.27 20 20,4 452 935 397 702 78 2532
1.28 20 20,7 1515 871 322 825 −57 2200
1.29 20 19,78 910 865 131 378 340 3150
1.30 20 20,4 2093 893 279 807 40 2161
While the surface of HA implant is very rough, compared to
the lightweight more uniform microcrystalline structure of
AO [33], wrapping the orbital implant allows attachment of
the extraocular muscles. A ﬁbrovascular capsule of variable
thicknessformsexternaltothepolyglactinmeshandreplaces
it by 12 weeks. Polyglactin 910 mesh-wrapped HA implants
must be placed deeply into the orbit with adequate soft tissue
coverage to oﬀset a higher exposure risk [17].
Vascularisation of an unwrapped HA implant takes
approximately 6 months; however when the HA implant is
wrapped with polyglactin mesh the speed of vascularisation
is more variable [18]. In vitro ﬁbroblasts and osteoblasts
proliferate more rapidly on the aluminium oxide compared
to HA suggesting the more biocompatible feature [34, 35].
Animal studies of HA implants showed evidence of soft-
tissue ingrowth into the material. Shields et al. reported the
ﬁrst histopathologic evidence of ﬁbrovascularisation of this
implant in the human orbit and showed that the implant was
partiallyvascularisedasearlyas4weeksafterplacement[32].
Gadolinium-enhanced MRI is a well-known method
to follow ﬁbrovascular ingrowth into polyethylene orbital
implants. MRI showed no inﬂuence on the ﬁbrovascular
ingrowth into orbital implants whether enucleation or
evisceration was performed using an animal study [36]. MRI
showed that HA implants took longer to allow ﬁbrovascular
ingrowth [15, 16]. A retrospective study of 45 patients
withorbitalimplantswhounderwentgadolinium-DTPAT1-
weighted MR imaging showed homogenous vascularization
with an intense enhancement pattern suggesting adequate
vascularingrowthafter5to6monthsfollowingimplantation
[14]. Potential implant failure may also be predictable with
MRI scanning [37].
Bone scanning using 99mTc (technetium) methylene
diphosphonate (99mTc-MDP) bone scan is another method6 International Journal of Biomaterials
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Figure 9: Scatter plot of the time between implantation and the HU (density). Conventionally noncalibrated and noncorrected plots. Linear
regression was applied to both implants separately. The excluded (n = 2) cases are also indicated.
to follow ﬁbrovascular ingrowth into orbital implants. Bone
scans however show that the orbital implants may be fully
penetrated by the 5th to 8th week following implantation
[38, 39]. Bone scans may be useful when the eﬀect of growth
factors is examined on HA orbital implants or with other
scaﬀolds [40]. Based on bone scan imaging the HA ﬁbrovas-
cularizationismorerapidthanporouspolyethyleneimplants
[41]. Nuclear medicine studies have great potential in future
implant and biomaterial evaluation [42]. A single-photon
emission computed tomography (SPECT) study showed that
increasing pore size of the implant was associated with a
higher rate vascular penetration while the amount of ﬁbrotic
tissue was decreased. The authors suggested the pore size to
be larger than 400 micrometers [43]. Future fusion of these
and other imaging modalities may become a reality. In fact
MRI has been used in the tissue engineering paradigm to
evaluate angiogenesis in certain scaﬀolds [44]. At the present
time MRI may be the best modality to assess angiogenesis
and ﬁbrovascular ingrowth but CBCT is simpler, without the
need for intravenous dye injection and with easier to install
equipment.
There are two major advantages in using ﬁbrovascu-
larised implants in the orbit. The implant is less likely to
extrude because it becomes biologically ﬁxed in the soft
tissues of the orbit. The implant is theoretically less likely to
become infected since the implant is incorporated with host
blood vessels within the recipient site with improved access
to the host immune defences [17].
In this study the MSCT control group was used to deter-
mine the maximal HU of the DV (2024.7HU ± 103.49HU)
and the mean density of CV (5.93HU ± 3.97HU) which
correspond to the CBCT. The CBCT calibrations were per-
formed within each scan with the CV mean and for the
DV maximum HU values as two well-deﬁned density values
corresponding to the control group.
This unique set of patients with implantation times
ranging from 79 to 2636 days provides an opportunity
to study the evolution of HUs of the implants over time
(Figure 9).
Correction equation for the noncalibrated values is
HUcorrected =
HUoi DVT −HUcv DVT
HUdv DVT −HUcv DVT
×(HUdv MSCT −HUcv MSCT)+HU cv MSCT.
(2)
The apparent density (HU) data from the remaining 28
implants (HA n = 17, AO n = 11) was plotted versus
the life span of the implant (days following implantation).
Linear regression was used to estimate the changes during
this period. The regression equations for both are indicated
on the plotted Figure 10.
Thefollowingtrendwasobservedbasedontheplots.The
HA implants show a corrected 10 HU decrease while AlO
decreases 14 HU on average on a yearly basis. Interpreting
theseresultsrequiresdiscriminationbetweenthehighappar-
entdensity (HU)oftheimplant materialsandthelow appar-
ent density of the surrounding and inﬁltrating ﬁbrovascular
structures. Taking this into account the decrease in HU levels
over the gross volume may represent the maturation, trans-
formation of the ﬁbrovascular ingrowth into the remaining
porous orbital implant or migration and possibly resorption
of the implant material in small portions.
Parts of the orbital implant which exceed the original
diameter of the implant were observed. There are spikes
around the marginal region of the orbital implant with
diﬀerent amounts in the lower nasal and temporal direction
(Figures 11 and 12). It is not clear if this is the part of the
orbital implant or a CBCT-related artefact.International Journal of Biomaterials 7
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Figure 10: Scatter plot of the time between implantation and the HU (density) with conventionally noncalibrated and corrected plots.
Figure 11:Frontalviewofvolumerenderingofthescannedvolume
with the orbital implant and the contralateral corpus vitreum.
The orbital implant volume within the factory implant diameter
(light blue) and beyond the factory implant diameter (red). The
contralateral orbit is represented as a gray sphere (patient ID 1.27).
Orientation, position, and bulk volume estimation are
possible with CBCT; however net volume measurements
were not made with settings used by the authors, because the
resolution of the acquisition is unable to detect the smaller
details of this structure.
The estimated diameter based on the 3-point ﬁtting
sphere drawing method showed a 0.2839mm standard devi-
ation compared to the manufacturer’s original value. This is
within the range of the actual acquisition technique resolu-
tion.
Since this is an in vivo study and none of the samples
required removal, there were no samples for decalciﬁcation
or histological evaluation.
5. Conclusions
Themajorgoalsofenucleationaretoremoveadiseasedglobe
which is intact and to provide the patient with cosmetically
acceptable appearance. HA orbital implants can be used for
long-term volume replacement after orbital enucleation.
Figure 12: Oblique lateral view of volume rendering of the scanned
volume with the orbital implant and the contralateral corpus
vitreum.Theorbitalimplantvolumewithin(lightblue)andbeyond
(red) the factory implant diameter. The contralateral orbit is
represented as a gray sphere (patient ID 1.27).
The general trend with decreasing implant density with
time is noted with both HA and AO implants populations
with and without HU correction, although the correction
makes the HU values more consistent. This tendency was
not conﬁrmed histologically because there were no failures
requiring removal of any of the orbital implants, leaving
no ethical way to biopsy or sample the surround orbital
soft tissues or the implants. Further studies in animals are
required to conﬁrm these ﬁnding with histological samples
and a highly standardized CBCT protocol.
The CBCT acquisition technique is attractive due to
its lower radiation exposure when compared to MSCT for
long-term orbital prosthesis monitoring. Such long-term
monitoring may require serial scanning of the same patient.
CBCTisanoninvasiveimagingmodalitysuitableforimplant
evaluation in terms of orientation, position, bulk volume,8 International Journal of Biomaterials
and gross density without the possibility of net volume
estimation. This CBCT study has provided a minimally inva-
sive platform for the future long-term evaluation of porous
calciﬁed implants and has provided some insights into
the long-term behaviour of hybrid polyglactin HA orbital
prosthesis.
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